Differential diagnosis of parkinsonism using dopamine transporters brain SPECT;Contribución de la SPECT cerebral de transportadores de dopamina en el diagnóstico diferencial de los parkinsonismos

Medicina Clinica

Volumn 122, Issue 9, 2004, Pages 325-328

  Bosquet, Caries Lorenzo ^a   Rodríguez, Francesc Miquel ^a   Bielsa, Isabel Roca ^a   Milà, Marta ^a   Aguadé Bruix, Santiago ^a   Conesa, Joan Castell ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

(123I) FP CIT; Dopamine transporters; Parkinsonism; SPECT

Indexed keywords

DAT SCAN; DOPAMINE TRANSPORTER; FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; IODINE 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; CARRIER PROTEIN; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; NERVE PROTEIN; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; ESSENTIAL TREMOR; HUMAN; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PARKINSONISM; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BASAL GANGLION; BRAIN; COMPARATIVE STUDY; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

AGED; BASAL GANGLIA; BRAIN; CARRIER PROTEINS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 2442665608     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059042     Document Type: Article

References (32)

1. De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, López-Pousa S, et al. Prevalence of the parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-5.
2. Lang AE, Lozano AM. Parkinson's disease. N Engl J Med 1998;339:1044-53.
3. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-8.
4. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002;73:529-34.
5. Bain PG. The management of tremor. J Neurol Neurosurg Psychiatry 2002;72(Suppl I):3-9.
6. Brooks DJ. Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2002;72(Suppl I):10-6.
7. 123I] (-FP-CIT study group. Mov Disord 2000;15:503-10.
8. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of B-CIT. J Nucl Med 1996;37:1129-33.
9. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-5.
10. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-40.
11. 123I]FP-CIT SPECT in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266-72.
12. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
13. The Consensus Commitee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996;46:1470.
14. Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinico-pathological study. Neurology 1997;48:119-25.
15. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of the progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
16. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
17. Martí Massó JF, Poza JJ. Parkinsonismo inducido o agravado por fármacos: características clínicas y evolución histórica de los fármacos implicados. Neurología 1996;11:10-5.
18. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102.
19. Findley LJ, Koller WC. Definitions and behavioural classifications. En: Findley LJ, Koller WC, editors. Handbook of tremor disorders. New York: Marcel Dekker, 1995; p. 1-5.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
21. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. En: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Vol. II. Florham Park: MacMillan Healthcare information 1987; p. 153-63.
22. Gerschlager W, Bencsits G, Pirker W, Bloem BR, Asenbaum S, Prayer D, et al. [123]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17:518-23.
23. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;876:876-80.
24. 123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415-21.
25. Tissingh G, Bergmans P, Booij J, Winogrodzka A, Van Royen EA, Stoof JC, et al. Drug-native patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [I-123]β β-CIT SPECT. J Neurol 1998;245:14-20.
26. 123I]FP-CIT SPECT in the demostration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71.
27. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, Van Royen EA, et al. Iodine-123-N-ω-fluoropropyl-2-β-carbomethoxy-3β -(4-iodophenyl)tropane SPECT in healthy controls and early stage, drug native Parkinson's disease. J Nucl Med 1998;39:1143-8.
28. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, et al. Relationship between the apperance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853-61.
29. Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ, et al. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003;126:312-25.
30. 123I]FP-CIT SPECT in healthy volunteers. Eur J Nucl Med 2000;27:867-9.
31. Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50(1): 34-41.
32. Wolters ECH, Berendse HW. The role of dopamine transporter-SPECT in Parkinson, early (preclinical) diagnosis and (putative) protective treatment in Parkinson's disease. En: Wolters EC, Tolosa E, editors. New tools in the diagnosis of parkinsonism. Current issues in neurodegenerative diseases. Vol. 13. Utrecht: Academic Pharmaceutical Productions, 2001; p. 69-87.